Scopus İndeksli Açık & Kapalı Erişimli Yayınlar
Permanent URI for this communityhttps://hdl.handle.net/11727/10752
Browse
3 results
Search Results
Item Effects of Combined Visible and Infrared Light Rhinophototherapy in Patients With Allergic Rhinitis(2023) Koycu, Alper; Bas, Ceren; Musabak, Ugur H.; Erbek, Selim Sermed; Koca, Huseyin Samet; Babakurban, Seda Turkoglu; Bahcecitapar, Melike; https://orcid.org/0000-0003-1290-3509; 36266929; AAF-3650-2021Background Intranasal phototherapy offers an alternative treatment method for patients with allergic rhinitis who cannot benefit from intranasal corticosteroids and oral antihistamines. Different wavelengths have been tried with promising results. Objective In this present study, we aimed to investigate the effects of visible light-infrared light phototherapy on clinical improvements together with its cytologic effects in patients with allergic rhinitis. Methods Patients with confirmed allergic rhinitis were given a 4-week course of intranasal phototherapy treatment. Weekly symptom questionnaires were applied to monitor clinical effects. Nasal lavage specimens were obtained before the start and at the completion of the 4-week therapy. Fluorescence-activated cell sorting analyses of CD16(+), CD24(+), and CD 45(+) cells were performed. Statistical analyses are performed of weekly changes in symptoms and cell counts. Results CD45(+)CD16(high)CD24(+) neutrophil count in nasal lavages decreased significantly whereas CD45(+)CD16(dim/-)CD24(+) eosinophil counts significantly increased and CD45(+) granulocyte counts remained unchanged. Symptom scores including nasal itching, nasal discharge, nasal obstruction, sneezing, eye itching, throat itching, and ear itching all statistically decreased compared to baseline at the end of 4 weeks. Conclusion Four-week course of intranasal phototherapy with visible and infrared light leads to clinical improvement in allergic rhinitis patients.Item Olfactory disorders in patients with mild to moderate COVID-19: spontaneous recovery in one-month follow up(2021) Inan, Serhat; Ozer, Fulya; Erbek, Selim Sermed; Caylakli, Fatma; Odemis, Ilker; Kursun, Ebru; 0000-0003-2638-0163; 0000-0001-5381-6861; 0000-0001-8821-4481; 0000-0002-7333-2896; AFK-3690-2022; AAJ-1407-2021; AAG-2486-2022; ABC-1809-2020; AAP-7195-2020Objective: In this study, we aimed to evaluate olfactory disorders (OD) and recovery processes in patients with coronavirus disease 2019 (COVID-19) infection at three time periods within one month from the time of diagnosis. Methods: A total of 96 patients with COVID-19 participated in the study. Self-reported changes in olfactory functions and their effects on quality of life (QoL) were evaluated using the National Health and Nutrition Examination Survey, the Questionnaire of Olfactory Disorders-Negative Statements (QOD-NS), and Sino-Nasal Outcome Test (SNOT)-22. At the time of diagnosis, the patients were divided into three groups: anosmia, hyposmia, and no OD (control) group. Subsequently, olfactory functions were retested at the time of the first negative polymerase chain reaction (PCR) control test and one month from the time of diagnosis. Results: During the COVID-19 infection, 68.7% of patients had OD; of these, 37% had anosmia, and 29% had hyposmia. Dysgeusia was found in 44.8% of the patients. OD was the primary symptom in 10.8% of the patients. The QoL scores of those with anosmia and hyposmia were significantly lower than those with no OD in all three surveys (P <.05). The QOD-NS scores of those with OD lasting more than 14 days were significantly lower in all three surveys (P <.05). Of the patients with OD, 4.34% had no spontaneous recovery at the end of the first month. Conclusion: Recovery of OD is faster in patients with hyposmia than in those with anosmia. Although COVID-19related permanent OD is not commonly observed, treatment of OD that lasts for more than 15 days would be beneficial to avoid permanent sequelae.Item The Effect of Postmenopausal Osteoporosis on Middle Ear Resonance Frequency(2021) Baytaroglu, Berk; Jafarov, Sabuhi; Erbek, Selim Sermed; 35177390BACKGROUND: The effect of postmenopausal osteoporosis on the middle ear mechano-acoustic system is unknown. The aim of this study is to investigate whether or not middle ear resonance frequency is affected in females with postmenopausal osteoporosis. METHODS: The study included postmenopausal women aged 45-60 years, separated into 2 groups as females with postmenopausal osteoporosis and healthy postmenopausal females (control group). A detailed anamnesis was taken from all subjects and then the ear, nose, and throat examinations were done followed by pure tone audiometry, tympanometry, and multifrequency tympanometry tests. The groups were compared in respect of pure tone average, bone conduction threshold, RF, static admittance, and tympanometric peak pressure values. RESULTS: The mean age of the patients was 59.2 +/- 4.53 years (range, 48-65 years) in the postmenopausal osteoporosis group and 57.11 +/- 4.27 years (range, 48-65 years) in the control group (P>.05). The mean resonance frequency values for the postmenopausal osteoporosis and control group were 954.41 +/- 127.47 and 935.29 +/- 126.39 Hz (P>.05). The mean static admittance values for the postmenopausal osteoporosis and control group were 0.82 +/- 0.33 and 0.85 +/- 0.3 mmho, and mean tympanometric peak pressure values were -7.35 +/- 18.52 and -6.94 +/- 19.52 daPa (P>.05 for both static admittance and tympanometric peak pressure). The mean pure tone averagevalues for the postmenopausal osteoporosis and control group were 20.96 +/- 6.82 and 15.60 +/- 7.81 dB, and mean bone conduction threshold values were 17.57 +/- 6.03 and 12.10 +/- 6.52 dB (P<.05 for both pure tone average and bone conduction threshold). CONCLUSIONS: The results showed that the middle ear resonance frequency values were not affected in postmenopausal osteoporosis patients, but there was seen to be greater sensorineural hearing loss in females with postmenopausal osteoporosis compared to healthy postmenopausal females.